VYONDYS 53

(golodirsen) 100 mg/2 mL injection

DOSING & ADMINISTRATION GUIDE

SareptaDMD.com/VYONDYS53

INDICATIONS AND USAGE

VYONDYS 53 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the *DMD* gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VYONDYS 53. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: VYONDYS 53 is contraindicated in patients with a serious hypersensitivity reaction to golodirsen or to any of the inactive ingredients in VYONDYS 53. Anaphylaxis has occurred in patients receiving VYONDYS 53.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions: Hypersensitivity reactions, including anaphylaxis, rash, pyrexia, pruritus, urticaria, dermatitis, and skin exfoliation have occurred in VYONDYS 53-treated patients, some requiring treatment. If a hypersensitivity reaction occurs, institute appropriate medical treatment and consider slowing the infusion, interrupting, or discontinuing the VYONDYS 53 therapy and monitor until the condition resolves. VYONDYS 53 is contraindicated in patients with a history of a serious hypersensitivity reaction to golodirsen or to any of the inactive ingredients in VYONDYS 53.

Kidney Toxicity: Kidney toxicity was observed in animals who received golodirsen. Although kidney toxicity was not observed in the clinical studies with VYONDYS 53, the clinical experience with VYONDYS 53 is limited, and kidney toxicity, including potentially fatal glomerulonephritis, has been observed after administration of some antisense oligonucleotides. Kidney function should be monitored in patients taking VYONDYS 53. Because of the effect of reduced skeletal muscle mass on creatinine measurements, creatinine may not be a reliable measure of kidney function in DMD patients. Serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio should be measured before starting VYONDYS 53. Consider also measuring glomerular filtration rate using an exogenous filtration marker before starting VYONDYS 53. During treatment, monitor urine dipstick every month, and serum cystatin C and urine protein-to-creatinine ratio every three months. Only urine expected to be free of excreted VYONDYS 53 should be used for monitoring of urine protein. Urine obtained on the day of VYONDYS 53 infusion prior to the infusion, or urine obtained at least 48 hours after the most recent infusion, may be used. Alternatively, use a laboratory test that does not use the reagent pyrogallol red, as this reagent has the potential to cross-react with any VYONDYS 53 that is excreted in the urine and thus lead to a false positive result for urine protein.

If a persistent increase in serum cystatin C or proteinuria is detected, refer to a pediatric nephrologist for further evaluation.

ADVERSE REACTIONS: Adverse reactions observed in at least 20% of treated patients and greater than placebo were (VYONDYS 53, placebo): headache (41%, 10%), pyrexia (41%, 14%), fall (29%, 19%), abdominal pain (27%, 10%), nasopharyngitis (27%, 14%), cough (27%, 19%), vomiting (27%, 19%), and nausea (20%, 10%).

Other adverse reactions that occurred at a frequency greater than 5% of VYONDYS 53-treated patients and at a greater frequency than placebo were: administration site pain, back pain, pain, diarrhea, dizziness, ligament sprain, contusion, influenza, oropharyngeal pain, rhinitis, skin abrasion, ear infection, seasonal allergy, tachycardia, catheter site related reaction, constipation, and fracture.

Other adverse events may occur.

To report **SUSPECTED ADVERSE REACTIONS**, contact Sarepta Therapeutics, Inc. at **1-888-SAREPTA** (1-888-727-3782) or FDA at **1-800-FDA-1088** or **www.fda.gov/medwatch.**

Before administration, please see the full US Prescribing Information for VYONDYS 53 (golodirsen).

TABLE OF CONTENTS

INTRODUCTION[1]

VYONDYS 53 should only be administered to patients who have a confirmed mutation of the *DMD* gene that is amenable to skipping exon 53.

VYONDYS 53 is contraindicated in patients with a serious hypersensitivity reaction to golodirsen or to any of the inactive ingredients in VYONDYS 53. Anaphylaxis has occurred in patients receiving VYONDYS 53.

Serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio should be measured before starting VYONDYS 53. Consider measurement of glomerular filtration rate prior to initiation of VYONDYS 53. Monitoring for kidney toxicity during treatment is recommended. Obtain the urine samples prior to infusion of VYONDYS 53 or at least 48 hours after the most recent infusion.

The recommended dose of VYONDYS 53 is 30 mg/kg administered once weekly as a 35 to 60 minute intravenous (IV) infusion via an in-line 0.2 micron filter. If a dose of VYONDYS 53 is missed, it may be administered as soon as possible after the scheduled dose.

Application of a topical anesthetic cream to the infusion site prior to administration of VYONDYS 53 may be considered.

Advise patients and/or caregivers that hypersensitivity reactions, including anaphylaxis, rash, pyrexia, pruritus, urticaria, dermatitis, and skin exfoliation have occurred in patients who were treated with VYONDYS 53. Instruct them to seek immediate medical care should they experience signs and symptoms of hypersensitivity.

Inform patients nephrotoxicity has occurred with drugs similar to VYONDYS 53. Advise patients of the importance of monitoring for kidney toxicity by their healthcare providers during treatment with VYONDYS 53.

VYONDYS 53 injection is supplied in single-dose vials containing 100 mg/2 mL (50 mg/mL) golodirsen. The solution is a clear to slightly opalescent, colorless liquid, and may contain trace amounts of small, white to off-white amorphous particles.

Store VYONDYS 53 at 2°C to 8°C (36°F to 46°F). Do not freeze. Store VYONDYS 53 in the original carton until ready for use to protect from light.

IMPORTANT SAFETY INFORMATION

- Adverse reactions observed in at least 20% of treated patients and greater than placebo were (VYONDYS 53, placebo): headache (41%, 10%), pyrexia (41%, 14%), fall (29%, 19%), abdominal pain (27%, 10%), nasopharyngitis (27%, 14%), cough (27%, 19%), vomiting (27%, 19%), and nausea (20%, 10%).
- Other adverse reactions that occurred at a frequency greater than 5% of VYONDYS 53-treated patients and at a greater frequency than placebo were: administration site pain, back pain, pain, diarrhea, dizziness, ligament sprain, contusion, influenza, oropharyngeal pain, rhinitis, skin abrasion, ear infection, seasonal allergy, tachycardia, catheter site related reaction, constipation, and fracture.

BEFORE THE INFUSION[1]

PROPER STORAGE AND HANDLING OF VYONDYS 53

Once you receive VYONDYS 53 at your facility, be sure to store it according to proper procedures:

Store VYONDYS 53 at 2° C to 8° C (36° F to 46° F)



Do not freeze

Store in the original carton until ready for use to protect from light



Please see the Indication and Important Safety Information on pages 2, 4 and 11, and the full Prescribing Information for VYONDYS 53 (golodirsen).

VYONDYS 53 (golodirsen) 100 mg/2 mL injection

VYONDYS 53 DOSING CALCULATIONS[1]

STEP 1 Calculate the patient dose in mg:
Patient weight (kg) x 30 mg/kg = total dose in mg of VYONDYS 53

STEP 2 Calculate the volume in mL:
Total mg of VYONDYS 53 needed ÷ **50** mg/mL = **Total volume in mL** of VYONDYS 53 needed
Rounded to the next higher mL

STEP 3 Calculate the number of single-dose vials the patient needs:
Total mL needed ÷ 2 = # of 2 mL vials

DOSING CALCULATION EXAMPLE BASED ON 33.5 KG PATIENT

STEP 1 Calculate the dose in mg:
33.5 kg x 30 mg/kg = 1,005 mg

STEP 2 Calculate the volume in mL:
1,005 mg ÷ 50 mg/mL = 20.1 mL = **21 mL** of VYONDYS 53
Rounded to the next higher mL

STEP 3 Calculate the number of single-dose vials:
21 mL = eleven 2 mL vials

Please see the Indication and Important Safety Information on pages 2, 4 and 11, and the full Prescribing Information for VYONDYS 53 (golodirsen).

VYONDYS 53 (golodirsen) 100 mg/2 mL injection

NECESSARY SUPPLIES[1,2]

To prepare VYONDYS 53, you will need:

VYONDYS 53
2 mL single-dose vials containing
100 mg golodirsen



0.9% Sodium Chloride Injection, USP,
(normal saline solution) infusion bag
(volume of 100-150mL)





0.2 micron filter

A syringe fitted with a 21-gauge
or smaller bore non-coring needle

PREPARING THE PUMP

Prepare the infusion pump and tubing as per the normal operating instructions for the make/model being used for the patient's infusion.

PREPARING VYONDYS 53 USING ASEPTIC TECHNIQUE[1,3]

PREPARE VYONDYS 53 ACCORDING TO THESE STEPS

STEP 1

Complete the dosing calculation.
See page 6 of this brochure for information on how to complete the dosing calculation.

STEP 2

Assess the patient's IV or port for patency prior to removing any vials from the refrigerator. If IV access is adequate, remove the appropriate number of vials from the refrigerator and allow them to warm to room temperature. Do not microwave vials.

STEP 3

Once at room temperature, mix the contents of each vial by gently inverting 2 or 3 times. Do not shake. Visually inspect each vial of VYONDYS 53. VYONDYS 53 is a clear to slightly opalescent, colorless liquid, and may contain trace amounts of small white to off-white amorphous particles. Do not use if the solution in the vials is cloudy, discolored or contains extraneous particulate matter other than trace amounts of small, white to off-white amorphous particles. If there is an issue with the solution, please report the issue to Sarepta at 1-888-SAREPTA (1-888-727-3782).

STEP 4

With a syringe fitted with a 21-gauge or smaller bore non-coring needle, withdraw the calculated volume of VYONDYS 53 from the appropriate number of vials.

STEP 5

Dilute the withdrawn VYONDYS 53 in 0.9% Sodium Chloride Injection, USP, to make a total volume of 100 to 150 mL. Before diluting VYONDYS 53, withdraw excess saline from the bag, if needed. Gently invert 2 to 3 times to mix. Do not shake. Visually inspect the diluted solution for particulates. Do not use if the solution is cloudy, discolored or contains extraneous particulate matter other than trace amounts of small, white to off-white amorphous particles.

VYONDYS 53 contains no preservatives and should be administered immediately after dilution. Complete infusion within 4 hours of dilution. If immediate use is not possible, the diluted product may be stored for up to 24 hours at 2° C to 8° C (36° F to 46° F). Do not freeze.

STEP 6

Application of a topical anesthetic cream to the infusion site prior to administration of VYONDYS 53 may be considered.

VYONDYS 53 is administered intravenously via an in-line 0.2 micron filter. Flush the patient's intravenous access with 0.9% Sodium Chloride Injection, USP, prior to and after infusion.



INFUSING VYONDYS 53[1,2]

ADMINISTER VYONDYS 53 ACCORDING TO THESE STEPS

STEP 7

- Flush the patient's intravenous access line with 0.9% Sodium Chloride Injection, USP, prior to infusion.
- Infuse the diluted VYONDYS 53 solution over 35 to 60 minutes via an in-line 0.2 micron filter.
- If a hypersensitivity reaction occurs, consider slowing the infusion, interrupting, or discontinuing the VYONDYS 53 therapy.
- Do not mix other medications with VYONDYS 53 or infuse other medications concomitantly via the same intravenous access with VYONDYS 53.
- After completion of the infusion, flush the intravenous access line with 0.9% Sodium Chloride Injection, USP, to allow the entire dose, including the contents of the intravenous access line, to be administered.
- In cases where VYONDYS 53 is administered into a venous access port, after administration of the drug and flushing with normal saline, the port may be flushed with heparin prior to de-access.

IMPORTANT ADDITIONAL INFORMATION

When administering VYONDYS 53 to patients with implanted infusion devices, access the device following the manufacturer's Instructions for Use to minimize the potential for infection.



Please see the Indication and Important Safety Information on pages 2, 4 and 11, and the full Prescribing Information for VYONDYS 53 (golodirsen).

VYONDYS 53 (golodirsen) 100 mg/2 mL injection

AFTER THE INFUSION[1]

STEP 8 Once you have completed the infusion, discard any unused product.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: VYONDYS 53 is contraindicated in patients with a serious hypersensitivity reaction to golodirsen or to any of the inactive ingredients in VYONDYS 53. Anaphylaxis has occurred in patients receiving VYONDYS 53.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions: Hypersensitivity reactions, including anaphylaxis, rash, pyrexia, pruritus, urticaria, dermatitis, and skin exfoliation have occurred in VYONDYS 53-treated patients, some requiring treatment. If a hypersensitivity reaction occurs, institute appropriate medical treatment and consider slowing the infusion, interrupting, or discontinuing the VYONDYS 53 therapy and monitor until the condition resolves. VYONDYS 53 is contraindicated in patients with a history of a serious hypersensitivity reaction to golodirsen or to any of the inactive ingredients in VYONDYS 53.

Kidney Toxicity: Kidney toxicity was observed in animals who received golodirsen. Although kidney toxicity was not observed in the clinical studies with VYONDYS 53, the clinical experience with VYONDYS 53 is limited, and kidney toxicity, including potentially fatal glomerulonephritis, has been observed after administration of some antisense oligonucleotides. Kidney function should be monitored in patients taking VYONDYS 53. Because of the effect of reduced skeletal muscle mass on creatinine measurements, creatinine may not be a reliable measure of kidney function in DMD patients. Serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio should be measured before starting VYONDYS 53. Consider also measuring glomerular filtration rate using an exogenous filtration marker before starting VYONDYS 53. During treatment, monitor urine dipstick every month, and serum cystatin C and urine protein-to-creatinine ratio every three months. Only urine expected to be free of excreted VYONDYS 53 should be used for monitoring of urine protein. Urine obtained on the day of VYONDYS 53 infusion prior to the infusion, or urine obtained at least 48 hours after the most recent infusion, may be used. Alternatively, use a laboratory test that does not use the reagent pyrogallol red, as this reagent has the potential to cross-react with any VYONDYS 53 that is excreted in the urine and thus lead to a false positive result for urine protein.

If a persistent increase in serum cystatin C or proteinuria is detected, refer to a pediatric nephrologist for further evaluation.

ADVERSE REACTIONS: Adverse reactions observed in at least 20% of treated patients and greater than placebo were (VYONDYS 53, placebo): headache (41%, 10%), pyrexia (41%, 14%), fall (29%, 19%), abdominal pain (27%, 10%), nasopharyngitis (27%, 14%), cough (27%, 19%), vomiting (27%, 19%), and nausea (20%, 10%).

Other adverse reactions that occurred at a frequency greater than 5% of VYONDYS 53-treated patients and at a greater frequency than placebo were: administration site pain, back pain, pain, diarrhea, dizziness, ligament sprain, contusion, influenza, oropharyngeal pain, rhinitis, skin abrasion, ear infection, seasonal allergy, tachycardia, catheter site related reaction, constipation, and fracture.

Other adverse events may occur.

To report **SUSPECTED ADVERSE REACTIONS**, contact Sarepta Therapeutics, Inc. at **1-888-SAREPTA** (1-888-727-3782) or FDA at **1-800-FDA-1088** or **www.fda.gov/medwatch.**

Before administration, please see the full US Prescribing Information for VYONDYS 53 (golodirsen).

SAREPTASSIST

Support, By Your Patients' Side

SareptAssist is a personalized support program here to help your patients on their treatment journey.

We can help:

- Understand the requirements for treatment
- Consider financial assistance options
- Explore your insurance benefits
- Prepare for treatment
- Find helpful resources
- Provide ongoing education and support

Get your patients started in 3 steps:

1. **Visit SareptAssist.com** and download the Enrollment Form (available in English and Spanish)
2. **Fill out the Enrollment Form** and fax it to SareptAssist at 1-800-621-5203
3. **A dedicated SareptAssist Case Manager** will contact your patient soon

Call 1-888-SAREPTA
(1-888-727-3782)

Case Managers are available Monday through Friday, 8:30 am – 6:30 pm ET

Spanish-speaking Case Managers and interpreters for other languages are available

References: 1. VYONDYS 53 [package insert]. Cambridge, MA: Sarepta Therapeutics, Inc. 2024. **2.** Data on file. Sarepta Therapeutics, Inc. **3.** Infusion Nurses Society. *Infusion Therapy Standards of Practice 2016*, Online edition. *Journal of Infusion Nursing*. Available at: http://ins.tizrapublisher.com/hai13r/. Accessed June 26, 2024.

SAREPTA THERAPEUTICS

09/24 C-SRP-53-US-0022-V4